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ABSTRACT Objective: Lack of effective therapies remains a problem in the treatment of oral squamous cell carcinoma (OSCC), especially in
patients  with  advanced  tumors.  OSCC  development  is  driven  by  multiple  aberrancies  within  the  cell  cycle  pathway,  including
amplification of cyclin D1 and loss of p16. Hence, cell cycle inhibitors of the CDK4/6-cyclin D axis are appealing targets for OSCC
treatment. Here, we determined the potency of palbociclib and identified genetic features that are associated with the response of
palbociclib in OSCC.
Methods: The effect of palbociclib was evaluated in a panel of well-characterized OSCC cell lines by cell proliferation assays and
further confirmed by in vivo evaluation in xenograft models. PIK3CA-mutant isogenic cell lines were used to investigate the effect
of PIK3CA mutation towards palbociclib response.
Results: We  demonstrated  that  80%  of  OSCC  cell  lines  are  sensitive  to  palbociclib  at  sub-micromolar  concentrations.
Consistently, palbociclib was effective in controlling tumor growth in mice. We identified that palbociclib-resistant cells harbored
mutations  in PIK3CA.  Using  isogenic  cell  lines,  we  showed  that PIK3CA mutant  cells  are  less  responsive  to  palbociclib  as
compared to wild-type cells with concurrent upregulation of CDK2 and cyclin E1 protein levels. We further demonstrated that the
combination of a PI3K/mTOR inhibitor (PF-04691502) and palbociclib completely controlled tumor growth in mice.
Conclusions: This study demonstrated the potency of palbociclib in OSCC models and provides a rationale for the inclusion of
PIK3CA testing in the clinical evaluation of CDK4/6 inhibitors and suggests combination approaches for further clinical studies.
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Introduction
Cancers that begin in the squamous cells  lining the mucosal
surfaces of the head and neck region, such as the oral cavity,
pharynx,  larynx,  salivary  glands,  and  nasal  cavity  are
collectively  termed  as  head  and  neck  squamous  cell
carcinoma (HNSCC). In 2012, oral squamous cell carcinoma
(OSCC),  the  most  predominant  type  of  HNSCC,  accounted
for an estimated 300,400 new cases worldwide and was the 8th
most  common  cancer  in  developing  countries  preceding
leukemia  and  non-Hodgkin  lymphoma1.  The  standard
treatments  for  OSCC  used  in  the  past  decades  include
surgery,  radiation  therapy,  and  chemotherapy.  Despite
advances  in  these  treatment  modalities  to  improve  survival
and  locoregional  control,  the  5-year  survival  rate  remains
below  60%2.  Moreover,  about  50%  of  patients  with  OSCC
present late at stage 3 and 43, resulting in a significant drop in
their  survival  rates4.  In  the  past  decade,  the  use  of  targeted
therapy  in  OSCC  was  previously  limited  to  cetuximab,  a
humanized  antibody  inhibiting  the  epidermal  growth  factor
receptor.  However,  the  clinical  benefit  of  cetuximab  with
chemotherapy  is  moderate,  with  only  2.7  months
improvement  in  overall  survival  as  compared  to
chemotherapy alone5.  Cetuximab treatment is  challenged by
primary  and  acquired  resistance  in  patients  with  OSCC6.
More  recently,  the  immune  checkpoint  inhibitors,
pembrolizumab  and  nivolumab,  were  approved  for  the
treatment  of  OSCC,  but  the  efficacy  of  immunotherapy  is
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only  seen  in  less  than  20%  of  patients7.  It  is  apparent  that
the  treatment  options  for  patients  with  OSCC  are
currently  limited,  especially,  for  patients  with  advanced
disease  and  who  are  refractory  to  chemotherapy,
underscoring the unmet need to increase effective treatment
options for such patients.
As OSCC is largely driven by several molecular changes
affecting the cell cycle, such as amplification of cyclin D1 and
loss  of  p168,  we  investigated  if  the  cell  cycle  inhibitor,
palbociclib, would be effective in treating OSCC. Palbociclib
is a specific CDK4/6 inhibitor and the first of its class to be
approved for breast cancer in combination with letrozole9
and  fulvestrant10.  In  OSCC,  the  use  of  palbociclib  in
combination  with  cetuximab  is  still  under  clinical
investigation11  and preclinical  data evaluating palbociclib
are  currently  limited.  Here,  we  demonstrate  the  effect
of  palbociclib  on  a  panel  of  well-characterized  OSCC
cell  lines  and  subcutaneous  xenograft  models.  Using
genomic  information of  these  well-characterized  models,
we  seek  to  identify  molecular  aberrancies  that  could
modulate  the  response  of  OSCC  to  palbociclib,  thereby
defining new precision therapeutic options for this aggressive
malignancy.
Materials and methods
Chemical reagents
Palbociclib was purchased from LC Laboratories (MA, USA).
Ribociclib,  abemaciclib,  and  PF-04691502  were  purchased
from  Selleckchem  (TX,  USA).  For in  vitro use,  all  reagents
were  dissolved  in  10  mM  stocks  (palbociclib  and  PF-
04691502 in DMSO, ribociclib and abemaciclib in water) and
kept as small  aliquots in –20°C until  further use.  For in vivo
experiments,  palbociclib and PF-04691502 were dissolved in
133 mg/mL and 25 mg/mL stocks, respectively, in DMSO and
stored at –20°C until further use.
Cell lines
The  ORL  series  used  in  this  study  was  established  from
patients with oral cancer as previously reported12, 13. All ORL
cell  lines  were  cultured  in  Dulbecco’s  modified  Eagle’s
medium/Nutrient  mixture  F12-Ham’s  medium  (DMEM/
F12; Hyclone, UT, USA) supplemented with 10% (v/v) heat-
inactivated  fetal  bovine  serum  (FBS;  Gibco,  Auckland,  NZ)
and  500  ng/mL  of  hydrocortisone  (Sigma-Aldrich,  MO,
USA).  Generation  of  CAL27/PIK3CAH1047R+ was  described
previously14. CAL27, CAL27/PIK3CAH1047R+ and MCF-7 cells
were grown in DMEM (Gibco, Auckland, NZ) supplemented
with 10% (v/v) heat-inactivated FBS. All cell lines have been
authenticated  to  tissues  and/or  blood  from  corresponding
patients as described previously12. Cells were cultured at 37 °C
in a 5% CO2 humidified atmosphere.
Crystal violet cytostatic assay
The cytostatic effect of palbociclib on a panel of OSCC lines
was determined by crystal violet cytostatic assay. Briefly, 8 ×
103 cells  were  seeded  in  triplicates  in  12-well  plates  and
following  overnight  incubation,  cells  were  exposed  to
palbociclib at  concentrations  ranging  from  0.008–2  μM  or
vehicle control [0.5% (v/v) DMSO]. After 72 h of incubation,
crystal  violet  solution  consisting  of  2%  (w/v)  crystal  violet
(Sigma Aldrich, MO, USA), 10% (v/v) formaldehyde (Merck
Millipore, MA, USA), and distilled water was added into each
well  and the  plates  were  further  incubated  for  an  additional
10  min  with  agitation.  The  crystal  violet  solution  was  then
removed from each well  and cells  were washed 2 times with
water  and  dried  overnight.  The  following  day,  the  resulting
crystals  were  dissolved  in 500 μL of  DMSO  and  the
absorbance  was  measured  at  590  nm  using  a  Synergy  H1
Multi-Mode  reader  (BioTek  Instruments,  VT,  USA).  The
concentration  of  drug  required  to  cause  50%  reduction  in
cell growth was calculated as GI50 = [(Absp – Abs0)/(AbsDMSO
–  Abs0)]  ×  100%,  where  Abs0 is  the  absorbance  value  of
untreated  cells  at  day  0,  and  Absp and  AbsDMSO are  the
absorbance values of palbociclib-treated and VC-treated cells
after 72 h, respectively.
Click-iT EdU cell proliferation assay
Cell proliferation was determined by the Click-iT EdU assay
(Invitrogen,  CA,  USA)  following  the  manufacturer’s
instructions.  Briefly,  7  ×  104 cells  per  well  were  grown
overnight on  glass  coverslips  and  treated  with  0.06–0.5  μM
palbociclib  or  0.5%  (v/v)  DMSO  for  24  h.  Cells  were
incubated with  10  μM  5-ethynyl-2′-deoxyuridine  (EdU)  for
2–6  h  prior  to  fixation  with  3.7%  (v/v)  formaldehyde.  The
cells  were  permeabilized  with  0.1%  (v/v)  Triton  X-100  in
phosphate  buffer,  followed  by  EdU  detection via a  copper-
catalyzed reaction and nuclei staining by Hoechst 33342. The
coverslips  were  then  mounted  on  glass  slides  using
VECTASHIELD®  Mounting  Medium  (Vector  Laboratories,
Burlingame,  CA, USA).  Slides were examined on an upright
Olympus  IX71  microscope  (Olympus,  Japan)  with  double
bandpass filters to detect fluorescent-stained nuclei (Hoechst
33342-excitation  360–370  nm  and  emission  420  nm)  and
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Alexa-labeled  EdU  (Alexa  647:  excitation  650  nm  and
emission 667 nm). Images were captured from 10 randomly
chosen  fields  of  each  experiment  and  analyzed  with  the
QuickCount®  software.  The  number  of  EdU-positive  cells
and  Hoechst  33342-stained  cells  was  counted  and  the
percentage  of  EdU-positive  cells  was  calculated  (from  three
independent  experiments)  using  the  following  formula:
number  of  EdU  positive  cells/number  of  Hoechst  33342-
stained cells × 100. EdU-positive cells broadly represent cells
that are undergoing DNA synthesis, whereas Hoechst 33342-
stained cells represent all cells in the same field.
Cell cycle assay
Briefly,  7  ×  104 cells  were  seeded  per  well  in  12-well  plates
and treated  with  0.06–0.5  μM  palbociclib  or  0.5%  (v/v)
DMSO  on  the  following  day  for  24  h.  All  floating  and
attached cells were harvested and fixed in 70% (v/v) ethanol
for  16 h at  –20°C.  Prior  to  analysis,  fixed cells  were  pelleted
and  washed  in  cold  phosphate  buffered  saline,  followed  by
staining with  10  μg/mL  propidium  iodide  solution
containing 20 μg/mL RNase for 30 min at  21°C in the dark.
Stained  cells  were  analyzed  by  BD  FACSCanto  IITM flow
cytometer  (BD  Biosciences,  MA,  USA)  with  10,  000  events
collected  for  each  reading.  The  distribution  of  DNA  in
different  phases  was  determined  using  the  ModFit  software
(Verity  Software  House,  USA).  The  percentage  of  cells  in
each  phase  was  calculated  from  three  independent
experiments.
Western blot
Palbociclib (0.06–0.5  μM)-treated  and  0.5%  (v/v)  DMSO-
treated cells were lysed on ice in lysis buffer [5 M NaCl, 10%
(v/v)  NP-40,  1  M  Tris  pH  8.0,  and  0.5  mM  DTT]
supplemented  with  HALT  protease  and  phosphatase
inhibitor  cocktail  (Pierce  Biotechnology,  IL,  USA).  Cell
lysates were then centrifuged at 13,000 × g for 10 min at 4°C
prior to estimation of protein content using the BCA method
(Thermo  Fisher  Scientific,  MA,  USA).  For  Western  blot
analysis, 30  μg  of  total  cellular  proteins  was  resolved  on  a
12%  (w/v)  sodium  dodecyl  sulfate-polyacrylamide  gel  and
electrotransferred  onto  Immobilon-P  membrane  (PVDF;
Millipore,  MA,  USA)  at  100  V for  1.5  h  on ice.  Membranes
were  blocked  with  5%  (v/v)  skimmed  milk  in  Tris-buffered
saline with 0.1% (v/v) Tween 20 (TBST; Sigma-Aldrich, MO,
USA)  for  1  h  and  then  probed  overnight  at  4°C  with  the
indicated  primary  antibodies  at  1:1000  dilution  in  1%  (v/v)
bovine  serum  albumin  in  TBST  [pRb  (S780),  pRb  (S795),
total  Rb1, cyclin D1, cyclin E1, CDK2, CDK4, CDK6, pAKT
(S473), total AKT1, pS6, total S6 (Cell Signaling Technology,
MA, USA), and α-tubulin (Sigma-Aldrich, MO, USA)]. Next,
membranes  were  washed  3  times  in  TBST  for  5  min  each.
Membranes  were  then  incubated  with  the  corresponding
horseradish  peroxidase  (HRP)-conjugated  secondary
antibodies (Southern Biotech, AL, USA) at 1:10,000 dilution
in  5%  (v/v)  skimmed  milk  in  TBST  for  1  h  at  room
temperature. This was followed by 3 washes in TBST prior to
detection  by  WesternBright  Quantum  HRP  substrate
(Advansta  Inc.,  CA,  USA)  and  visualization  using  the
FluorChemTM HD2  imaging  system  (ProteinSimple,  CA,
USA).
In vivo mouse experiments
Six-week-old  female  NOD/SCID  mice  were  subcutaneously
implanted with 2 × 106 cells in both flanks. When the tumors
reached  the  size  of  approximately  100–200  mm3,  the  mice
were  randomized  into  experimental  groups:  vehicle  control
(VC),  palbociclib  (150  mg/kg  body  weight,  suspended  in
DMSO 5%  and  Cremophor-EL  10%,  500  μl  p.o),  or  PF-
04691502  (10  mg/kg  body  weight,  suspended  in  DMSO  4%
and 0.5%  methylcellulose,  200  μL  p.o).  Treatment  was
administered  daily  by  oral  gavage  for  21  days  and  tumor
measurements  were  taken  using  a  digital  calliper  every  3–4
days  throughout  the  experiment.  Tumor  volumes  (V)  were
calculated  as  V  =  ½  length  ×  (width)2.  Growth  curves  were
plotted  as  an  average  tumor  volume  of  each  experimental
group against  the set  time points.  At the end of experiment,
mice  were  sacrificed  and  tumors  were  harvested  for  tissue
processing  and  histopathological  analysis.  All  procedures
involved in the animal study were reviewed and approved by
the  Animal  Ethics  Committee  of  Universiti  Kebangsaan
Malaysia  (Approval  No.  CARIF/2016/CHEONG/18-
MAY/762-JUNE-2016-JUNE-2019).
Statistical analysis
All  data  are  expressed  as  mean  ±  standard  deviation  (SD)
from three independent experiments unless stated otherwise.
Statistical  analysis  was  performed  using  IBM  SPSS  Statistics
for  Windows,  version  21.0  (IBM  Corp.,  NY,  USA).
Significant  differences  between  groups  were  analyzed  using
2-tailed  independent t-test  or  one-way  analysis  of  variance
(ANOVA).  A P-value  less  than  0.05  was  considered
statistically significant.
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Results
Palbociclib inhibits the growth of OSCC cells
in culture
To examine  the  effect  of  palbociclib  on  OSCC,  we  treated  a
panel of OSCC cell lines with 0–2 μM of palbociclib for 72 h.
Among  the  16  OSCC  cell  lines  tested,  13  were  sensitive  to
palbociclib  with  a  GI50 (concentration  for  50%  of  maximal
inhibition of cell growth) of less than 1 μM, while three lines
with  a  GI50 of more  than  1  μM  indicated  resistance  to
palbociclib  based  on  the  cytostatic  assay  (Figure  1A).  The
sensitive  and  resistant  groups  were  significantly  different
from  each  other  with  ~5-fold  differences  in  average  GI50
values (P < 0.01). To further validate the inhibitory effect of
palbociclib on cell proliferation, we performed Click-iT EdU
proliferative assay on representative palbociclib-sensitive cells
(CAL27  and  ORL-48)  and  palbociclib-resistant  cells  (ORL-
150  and  ORL-115).  Relative  to  the  VC  group,  palbociclib
treatment (0.06  to  0.5  μM) for  24  h  reduced the  number  of
EdU-positive  cells  (represented  as  red  stained-cells)  in
CAL27  and ORL-48  cells  (Figure  1B),  suggesting  a  decrease
in  DNA  synthesis  activity  and  blockade  of  cell  cycle
progression from G1 to S phase. As expected, the reduction in
EdU-positive  cells  was  not  as  pronounced  in  ORL-150  and
ORL-115 cells  where  the  reduction in  dividing cells  was  less
than 50% even at the highest drug concentration (Figure 1B
and 1C).
Anti-proliferative activity of palbociclib is due
to G1 cell cycle arrest
As  a  selective  inhibitor  of  CDK4/6,  palbociclib  is  known  to
prevent the initiation of S phase of the cell cycle. To confirm
this,  we  next  investigated  the  anti-proliferative  effect  of
palbociclib  through  cell  cycle  analysis  following  propidium
iodide  staining  in  palbociclib-sensitive  CAL27  and  ORL-48
cells. The cells were treated with palbociclib (0.06 to 0.5 μM)
for  24  h.  Palbociclib  treatment  increased  the  percentage  of
cells  in  the  G0/G1 phase,  and  concurrently  reduced  the
percentage  of  S  phase  cells  in  a  dose-dependent  manner  for
both cell lines (Figure 1D). This indicates the inhibition of S
phase initiation by palbociclib, which resulted in the arrest of
cell  cycle  progression  at  the  G0/G1 phase  in  OSCC  cells.
Palbociclib did not induce death in CAL27 and ORL-48 cells
as seen by the constant level of cell population in the sub-G1
phase  across  the  different  treatment  doses  (Supplementary
Figure S1).
Palbociclib reduces Rb protein levels and
phosphorylation
We further investigated the biochemical effect of palbociclib
on  proteins  involved  in  the  Rb  pathway,  which  is  critical  in
regulating  the  initiation  of  DNA  replication.  We  first
performed  a  dose-dependent  protein  expression  analysis  on
palbociclib-sensitive  (CAL27  and  ORL-48)  and  palbociclib-
resistant  cells  (ORL-150  and  ORL-115)  for  Rb
phosphorylation  at  S780,  S795,  and  S807/811  as  these  sites
are known to be phosphorylated by CDK4/615.  We observed
that treatment with palbociclib, especially at 0.5 μM, reduced
Rb  phosphorylation  at  all  three  phosphorylation  sites  in
CAL27,  ORL-48,  and  ORL-150  cells  (Figure  1E),  indicating
the  blockage  of  cell  cycle  progression  upon  palbociclib
treatment. In contrast, ORL-115 cells retained the expression
and phosphorylation of Rb at all doses tested (0.06–0.5 μM),
validating the  resistance of  this  cell  line  towards  palbociclib,
as  shown  in  the  proliferative  assays  described  above.  As  the
greatest  effect  of  Rb  dephosphorylation  was  observed  at  0.5
μM  dose,  this  concentration  was  used  to  conduct  a  time-
dependent protein expression analysis of palbociclib-sensitive
cells  (CAL27  and  ORL-48).  Complete  dephosphorylation  of
Rb  was  observed  after  24  h  of  palbociclib  treatment,
particularly  at  S780  and  S795  (Figure  1F).  Additionally,
palbociclib steadily downregulated the expression levels of Rb
in  a  time-dependent  manner,  culminating  in  low  Rb
expression at 24 h after treatment in both cell lines. We also
noted that the protein levels of cyclin D1, CDK4, and CDK6
were  slightly  increased  with  time  as  a  result  of  palbociclib
treatment,  consistent  with  observations  in  other  studies  on
breast and colorectal cancers16,17.
Palbociclib inhibits tumor growth in
subcutaneous xenograft model
As  demonstrated  earlier,  palbociclib  exerted  potent
inhibitory  effect  on  OSCC  cell  growth in  vitro.  Next,  we
investigated in  vivo efficacy  of  palbociclib  in  subcutaneous
xenograft models using CAL27 and ORL-48 cells. Mice were
randomized to receive either 150 mg/kg of palbociclib or VC
when  tumors  reached  an  average  volume  of  100–150  mm3.
We  observed  that  palbociclib  treatment  for  21  days
significantly  inhibited  the  growth  of  CAL27  (VC:  477.5  ±
101.2  mm3 vs.  palbociclib:  159.76  ±  22.6  mm3; P =  0.007)
and ORL-48 (VC: 755.06 ± 51.07 mm3 vs.  palbociclib: 68.47
± 15.07 mm3, P = 1 × 10–7) xenograft tumors (Figure 2A and
2B).  Next,  we  investigated  the  expression  and
phosphorylation of Rb protein in xenograft tumors that were
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Figure 1   Majority of OSCC cell lines were sensitive to palbociclib. (A) Crystal violet cytostatic assay performed on a panel of OSCC cell lines
showed GI50 of less than 1 μM in 80% of the cell lines tested, while three lines (ORL-188, ORL-150 and ORL-115) indicated resistance
(GI50>1μM).  Cell  lines were treated with 72h of 0.008 to 2 μM of palbociclib.  (B,C) Cytostatic effect of palbociclib was validated in
representative sensitive and resistant cell lines using Click-iT EdU assay. Blue (Hoecsht 33342) represents the total number of cells in any
field and red (Alexa 647) represents proliferating cells that have incorporated the EdU label. Palbociclib (24 h) exhibits anti-proliferative
effects on CAL27 and ORL-48 as demonstrated by the reduction in the percentage of EdU-positive cells which represents actively dividing
cells, but not observed in ORL-115. (D) Escalating dose of palbociclib (24 h) increased G0/G1 cell population in CAL27 and ORL-48 cells by
propidium iodide analysis. (E) Dose-dependent Western blot analysis of palbociclib showed reduction of Rb phosphorylation (greatest at 0.5 μM)
on CAL27, ORL-48 and ORL-150 but not on ORL-115. Cells were treated with the indicated concentrations for 24 h. (F) Time-dependent
Western blot analysis on sensitive cells indicated reduction of Rb phosphorylation within 24 h at 0.5 μM palbociclib treatment. Symbols *, **
and *** denote P < 0.05, P < 0.01, P < 0.001, respectively. Western blot results shown are representative of at least two independent
experiments.
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harvested  at  the  end  of  the  study.  As  shown  in Figure  2C,
palbociclib  treatment  resulted  in  the  reduction  in  Rb
phosphorylation  at  S795  in  CAL27  xenograft  tumors.  The
effect  was  more  apparent  in  ORL-48  xenograft  tumors,
wherein  reduction  in  Rb  phosphorylation  was  observed  at
both S780 and S795 sites, consistent with the observation that
tumor  volume  control  was  more  significant  in  this  cell  line
compared  to  that  in  CAL27  cells  (Figure  2A and 2B).
Although  we  observed  marked  reduction  in  Rb
phosphorylation  at  S780  and  S795,  Rb  phosphorylation  was
not  affected  at  S807/811  (Figure  2C),  which  was  consistent
with in  vitro observations  for  ORL-48  (Figure  1E).  In
addition, palbociclib treatment caused reduction in the total
Rb levels of both CAL27 and ORL-48 tumors, consistent with
that  observed in  vitro.  These  observations  confirmed  that
palbociclib  inhibited  the  CDK4/6-Rb  pathway,  which
eventually led to tumor control in mice.
Cancer cells harboring PIK3CA mutation are
less responsive to palbociclib
From our data, we observed that a subset of OSCC cell lines
was resistant to palbociclib.  We investigated whether certain
genetic  features  could  lead  to  palbociclib  resistance.  To
achieve  this,  we  compared  the  mutational  profiles  of
palbociclib-sensitive and -resistant cell lines as determined by
cytostatic assay in Figure 1A. We found that two out of three
cell  line  in  the  resistant  group carried  mutations  in PIK3CA
(H1047L  and  Q546R  in  ORL-115  and  ORL-150,
respectively)12,18,  while  none  of  the  palbociclib-sensitive  cell
lines had any mutations in this gene (P < 0.001; Figure 3A).
This  observation  was  validated  with  a  larger  data  set  from
Genomics of Drug Sensitivity in Cancer (GDSC) comprising
of  789  palbociclib-treated  cancer  cell  lines  of  all  available
cancer  types  in  the  database.  These  cell  lines  were  grouped
based on their PIK3CA mutational status [wild-type (WT) or
having any mutations in PIK3CA] and their geometric means
of  IC50 were  compared.  Cancer  cells  having  mutation  in
PIK3CA have  a  higher  geometric  mean  IC50,  implying  that
they  are  more  resistant  to  palbociclib  compared to  cell  lines
with  WT PIK3CA;  however,  the  difference  was  not
statistically significant (P = 0.101; Figure 3B). This led us to
further  investigate  the  role  of PIK3CA mutations  in
conferring palbociclib resistance in OSCC.
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Figure 2   Palbociclib controls OSCC xenograft tumors. (A) Mice bearing CAL27 and ORL-48 xenograft tumors were treated with either
vehicle control (VC) or 150 mg/kg palbociclib (Palbo) for 21 d. Palbociclib significantly inhibited growth of OSCC subcutaneous xenograft
ORL-48 and CAL27 tumors. Results shown are mean ± SEM (n = 10 tumors per group). Symbol *** denotes P < 0.001. (B) Representative
tumors harvested at the end of treatment showed decreased tumor volume in the palbociclib treatment group. (C) Western blot analysis on
proteins extracted from tumors at end-point showed palbociclib treatment reduced Rb phosphorylation in mouse tumors particularly at
S780 and S795 phosphorylation sites.
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PIK3CA mutation decreases response to
palbociclib
To  test  whether PIK3CA mutations  confer  resistance  to
palbociclib  in  OSCC,  we  used  CAL27  cells  that  were
previously  retro-engineered  to  stably  express PIK3CAH1047R
alteration14.  The  mutational  status  of PIK3CA in  isogenic
(mutant  and  WT)  CAL27  cell  lines  was  verified  by  Sanger
sequencing,  where  the  mutant  CAL27  cells  have  base
substitution from A (WT) to G, resulting in the replacement
of  histidine  (H)  with  arginine  (R)  at  position  1047
(Supplementary  Figure  S2A).  The  presence  of  the  H1047R
mutation  was  also  confirmed  by  western  blotting,  wherein
increased Akt  phosphorylation was observed in mutant  cells
(Supplementary Figure S2B).
The differential sensitivity to palbociclib in these isogenic
cells  was  first  evaluated  by  EdU  proliferation  assay.  The
inhibition of cell proliferation was more pronounced in WT
cells as the percentage of EdU-positive cells was observed to
be lower by ~4-fold compared to that in PIK3CA  mutant
cells at a dose of 0.5 μM (P < 0.001; Figure 4A and 4B). In
addition,  we  assessed  whether  the  presence  of  PIK3CA
mutation would affect the response to two other clinically
approved CDK4/6 inhibitors19,20. We treated isogenic CAL27
cells  with  ribociclib  and  abemaciclib  (0.25–0.5  μM)  and
found  that  the  number  of  EdU-positive  cells  was  also
significantly  lower  in  WT  cells  as  compared  to  that  in
PIK3CA  mutant cells (Figure 4C).  These results indicated
that the presence of PIK3CA mutation reduced the sensitivity
of CAL27 to CDK4/6 inhibitors, and this observation was not
restricted to palbociclib.
Next,  flow  cytometry  was  performed  to  evaluate  the
differences in G1 cell cycle arrest in the respective WT and
mutant  cells.  As  demonstrated  previously,  palbociclib
treatment arrests cells at the G0/G1 phase. As shown in Figure
4D, the percentage of cells in the G0/G1 phase for PIK3CA
mutant cell line was lower than that for WT cells at all doses
tested, with statistical significance at 0.5 μM palbociclib (P =
0.02).  Concurrently,  PIK3CA  mutant  cell  lines  showed
greater percentage of cells in the S phase than WT cells at 0.5
μM treatment dose (P  = 0.03), indicating higher cell cycle
activity, consistent with the results of palbociclib resistance.
PIK3CA mutant cells escape CDK4/6
inhibition via the CDK2 pathway
To  investigate  the  biochemical  mechanism  that  caused
PIK3CA mutant  cells  to  exhibit  higher  resistance  to
palbociclib,  proteins  were  extracted  from  the  isogenic  cells
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Figure 3   Palbociclib-resistant cell lines harbour PIK3CA mutation. (A) Comparison of the mutational status between sensitive and resistant
cells obtained from the cytostatic data of Figure 1A revealed significant association of PIK3CA mutation with palbociclib resistance. Symbol
*** denotes P < 0.001. (B) According to Genomics of Drug Sensitivity in Cancer (GDSC) database, cancer cells having any mutation in the
PIK3CA gene have higher geometric mean IC50, implying them to be more resistant to palbociclib compared to wild-type cancer cells. A
total number of 789 palbociclib-treated cancer cell lines of all available cancer types are included in the analysis.
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after  24  h  of  treatment  with  escalating  doses  of  palbociclib
(0.06  to 0.5 μM),  and  proteins  within  the  Akt  and  Rb
pathway were examined by Western blot (Figure 4E). Due to
the  presence  of  the PIK3CAH1047R mutation,  mutant  cells
showed  significantly  higher  phosphorylation  of  Akt  as
compared to WT cells across all palbociclib doses tested. The
reduction  in  Rb  phosphorylation,  particularly  at  S795  and
S807/811, was not as marked in PIK3CA mutant cells treated
with  palbociclib  as  compared  to  that  in  WT  cells.  Less
reduction  in  Rb  phosphorylation  at  the  S780  site  was  also
detected; however,  it  was  only  apparent  at  the  0.06  μM
treatment  dose.  Lack  of  reduction  in  Rb phosphorylation  at
S807/811  and  S795,  but  clear  reduction  at  S780  in  the
PIK3CA mutant  cells  suggested  an  S  phase  entry  through
phosphorylation of Rb by the CDK2/cyclin E1 complex15,21,22.
We noted that palbociclib treatment (0.06 to 0.5 μM) caused
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reduction  in  CDK2  expression  in  WT  cells,  however  CDK2
expression was sustained throughout the range of palbociclib
dose  tested  in  the  mutant  cells.  Cyclin  E1,  which  partners
with CDK2 to  phosphorylate  Rb,  showed increased levels  of
expression  in  the  mutant  cells  as  compared  to  those  in  WT
cells when palbociclib treatment was given. On the contrary,
we did  not  see  any  changes  in  CDK4,  CDK6,  and cyclin  D1
protein  levels  between  WT  and  mutant  cells  across  all
treatment doses, suggesting that the CDK2/cyclin E1 pathway
is  a  potentially  compensatory  pathway  that  led  to  Rb
phosphorylation  in PIK3CA mutant  cells,  resulting  in  an
escape from palbociclib treatment.
Combination of CDK4/6 and PI3K inhibitors
sensitizes the PIK3CA mutant cell line ORL-
115
Since PIK3CA mutations confer resistance to palbociclib, we
used the inherently  resistant  cell  line  ORL-115 to determine
whether PIK3CA mutant  cells  could  be  sensitized  to
palbociclib with a combination treatment targeting the PI3K
pathway.  Using  ORL-115,  which  harbors  the PIK3CAH1047L
mutation,  we  showed  that  treatment  with  a  combination  of
palbociclib  and  a  PI3K/mTOR  inhibitor  (PF-04691502)
substantially  increased  sensitivity  to  palbociclib,  where  the
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Figure 5   Palbociclib-resistant cell line was re-sensitized when co-inhibited with a PI3K/mTOR inhibitor. (A) From Click-iT EdU assay, ORL-
115 (naturally carrying a H1047L PIK3CA mutation) cells showed resistance to 0.5 μM palbociclib (24 h) in relative to CAL27 WT cells.
Combining the treatment with 0.25 μM PF-04691502 (a PI3K/mTOR inhibitor) significantly improved growth inhibition in ORL-115 cells.
Symbol *** denotes P < 0.001. (B) Western blot analysis of proteins extracted from ORL-115 cells treated with 0.5 μM palbociclib and 0.25
μM PF-04691502 (24 h) showed non-phosphorylated Rb and prevention of cell cycle kinases upregulations. (C) Mice bearing ORL-115
xenograft tumor were treated with either VC, palbociclib (150 mg/kg), PF-04691502 (10 mg/kg), or combination of both for 21 d. Only the
combination treatment resulted in the gradual decrease of tumor volumes. Results shown are mean ± SEM (n = 10 tumors per group). (D)
Representative ORL-115 xenograft tumor harvested at the end of experiment showed the greatest tumor inhibition from the combination
group.
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lowest  percentage  of  EdU-positive  cells  was  observed  in  the
combination  group  (Figure  5A).  Consistent  results  were
observed  for  ORL-150  (data  not  shown).  The  Western  blot
results  in  ORL-115  cells  indicated  that  treatment  with
palbociclib  alone  resulted  in  the  upregulation  of  cyclin  E1
and  sustained  levels  of  CDK2,  possibly  leading  to  Rb
phosphorylation  especially  at  S795  and  S807/811  sites
(Figure  5B).  Inhibiting  both  CDK4/6  and  PI3K  pathways
prevented  the  upregulation  of  cyclin  E1,  reduced  CDK2
levels,  and  resulted  in  the  accumulation  of  non-
phosphorylated  Rb  at  all  three  sites,  suggesting  improved
growth  inhibition  in  ORL-115  cells.  Additionally,  co-
treatment  with  PF-04691502  resulted  in  the  reduction  in
levels  of  other  cell  cycle  kinases,  such  as  CDK4,  CDK6,  and
cyclin  D1  as  compared  to  palbociclib  treatment  alone.
Consistently, in  vivo,  we  demonstrated  that  ORL-115  cells
were  less  responsive  to  palbociclib,  as  sustained  tumor
growth was still observed in animals treated with palbociclib,
with tumor volume steadily increasing from 112 mm3 (day 1)
to  296  mm3 (day  22)  throughout  the  treatment  period
(Figure 5C). Only when the combined treatment was given, a
sustained  tumor  volume  reduction  was  achieved  from
124 mm3 (day 1) to 76 mm3 (day 22). ORL-115 tumors that
were  treated  with  PF-04691502  also  demonstrated  better
tumor  growth  control  compared  to  those  treated  with
palbociclib; however, this was not as marked as compared to
the  combination  treatment  of  palbociclib  and  PF-04691502
(Figure 5C and 5D).
Discussion
Alterations  within  the  cell  cycle  machinery  are  common
molecular alterations found in HNSCC, including mutations
in TP53 (74%),  loss  of  p16  (49%),  and  amplification  of
CCND1 (28%)8.  These  alterations  implicate  the  use  of  cell
cycle inhibitors in OSCC. In recent years, cell cycle inhibitors
with targeted activity towards specific components of the cell
cycle have been developed and approved in a clinical setting
for  breast  cancer19,23.  Here,  we  describe  the  effects  of  the
CDK4/6 inhibitor palbociclib on OSCC cell  lines and tumor
models.  We  found  that  majority  of  the  OSCC  cell  lines
responded  to  palbociclib  treatment  with  concomitant
reduction  in  RB  phosphorylation,  which  resulted  in
inhibition of cell proliferation and G1 cell cycle arrest. The in
vitro observations  were  confirmed  by  significant  tumor
control  in  subcutaneous  mouse  models.  A  recent  Phase  I
clinical  trial  on  OSCC  also  reported  tumor  response  in
patients with OSCC treated with palbociclib, including those
previously  resistant  to  cetuximab  or  cisplatin11,  strongly
suggesting that palbociclib could be a promising therapeutic
drug for patients with OSCC.
Understanding the molecular changes that could influence
therapeutic response is vital for identifying subgroups that
are most likely to benefit  from palbociclib treatment.  We
leveraged on genomic information on well-characterized cell
lines12,18,24 and showed that PIK3CA mutations are associated
with the resistance of OSCC cell lines to palbociclib. Using
CAL27 isogenic cell lines, we confirmed that mutations in
PIK3CA  indeed confer resistance to palbociclib and other
clinically approved CDK4/6 inhibitors. In PIK3CA mutant
cell  lines, this resistance is accompanied by an increase in
cyclin E and CDK2 expression. PIK3CA mutations have been
shown  to  increase  the  expression  of  cyclins  and  their
dependent  kinases.  For  example,  in  a  non-tumorigenic
human breast epithelial cell line, PIK3CA mutations resulted
in the upregulation of cyclin D1, resulting in an increase in
cell proliferation25. Furthermore, upregulation of cyclin D1
and  CDK2-dependent  Rb  phosphorylation  by  PI3K
activation was also reported in MCF7 cells  in response to
CDK4/6 inhibition16. PIK3CA mutations were also previously
reported  to  increase  cyclin  E  expression,  where  PI3K-
dependent upregulation of cyclin E1 levels was associated
with acquired resistance to CDK4/6 inhibition in pancreatic
ductal adenocarcinoma26. PI3K activation can drive the cell
cycle  by regulating the expression of  cell  cycle  inhibitors,
including  p21  and  p27,  as  reported  previously27-29.
Furthermore,  PIK3CA  mutations  could  directly  regulate
cyclin  D levels  by  inhibiting glycogen synthase  kinase-3β
expression, resulting in the stabilization and localization of
cyclin D1 to the nucleus25,30. Based on our observation that
activation  of  PI3K  confers  resistance  to  palbociclib,  we
demonstrated  that  treatment  with  a  combination  of
palbociclib and a PI3K/mTOR inhibitor resulted in complete
tumor  growth  control  in  the  animal  model.  While
PI3K/mTOR inhibition alone was also able to delay tumor
growth, it was obvious that blocking PI3K signaling restored
sensitivity to palbociclib in OSCC models. Concurring with
our in vitro  observations, complete tumor growth control
was observed concomitantly with reduction in cyclin E1 and
CDK2 expression. This is consistent with data from other
studies  where  PI3K/mTOR  inhibitor  synergistically
cooperated  with  CDK4/6  inhibitor  in  suppressing  cell
proliferation  by  reducing  the  levels  of  critical  cell  cycle
regulatory proteins, such as cyclin E1, cyclin D1, CDK2, and
cyclin A26,31,32.
In summary, we demonstrated that palbociclib is effective
in controlling tumor growth in most OSCC cell lines. Our
data also revealed that PIK3CA mutational status may serve
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as a biomarker for response to palbociclib and other clinically
approved CDK4/6 inhibitors. Finally, we demonstrated that
simultaneous  inhibition  of  PI3K/mTOR  and  CDK4/6  is
effective in controlling tumor growth in resistant OSCC cell
lines.  Given that clinical  studies on CDK4/6 inhibitors in
OSCC have been initiated, our study provides a rationale for
testing  biomarkers  of  response  and  suggests  possible
combinatorial approaches for patients who may not respond
to CDK4/6 inhibitors as single agents.
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Figure S1   Escalating dose of palbociclib (24 h) did not change the sub-G1 cell population in CAL27 and ORL-48 cells by propidium iodide
analysis.
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Figure S2     CAL27 cells  were  previously  engineered to  stably
express PIK3CA (H1047R) alteration through retroviral infection.
(A) DNA chromatogram of WT and mutant CAL27 cells confirmed
base substitution from A (wild type; WT) to G (mutant) resulting in
the  change  of  amino  acid  R  at  position  1047.  (B)  Proteins
extracted from mutant CAL27 cells showed over-activation of Akt
(S473) but not in WT CAL27 cells by western blotting.
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